This is interesting based on clinical outcome data, which clearly demonstrates that FLT3-ITD-mutant AML with a co-existing NPM1 mutations have a more favourable prognosis that those with FLT3-ITD mutations and wild-type NPM1. This evidence concerns the gene FLT3 and acute myeloid leukemia.